EXAGEN INC. — Director's Dealing 2024

Nov 19, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EXAGEN INC. (XGN)
CIK: 0001274737
Period of Report: 2024-11-15

Reporting Person: Black Jeffrey G. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-15	Common Stock	P	22298	$2.98	Acquired	274492	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.25, inclusive. The reporting person undertakes to provide Exagen Inc., any security holder of Exagen Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this form 4.